Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Case Report, J Genet Disor Genet Rep Vol: 5 Issue: 4
Treatment with Agalsidase Alfa during Pregnancy in a Heterozygous Female with Fabry Disease
| Antonio Pisani1, Giuseppe Bifulco2, Attilio Di Spiezio Sardo3 and Eleonora Riccio1* | |
| 1Department of Public Health, Chair of Nephrology, Federico II University of Naples, Italy | |
| 2Department of Neuroscience, Division of Obstetrics and Gynecology, Reproductive and Odontostomatological Sciences, Federico II University of Naples, Italy | |
| 3Department of Public Health, Division of Obstetrics and Gynecology, Federico II University of Naples, Italy | |
| Corresponding author : Eleonora Riccio Chair of Nephrology, Department of Public Health, Federico II University of Naples, Naples, 80131, Italy Tel: +39 081 7464521 Fax: +39 081 7464521 E-mail: elyriccio@libero.it |
|
| Received: May 19, 2016 Accepted: July 22, 2016 Published: July 26, 2016 | |
| Citation: Pisani A, Bifulco G, Sardo ADS, Riccio E (2016) Treatment with Agalsidase Alfa during Pregnancy in a Heterozygous Female with Fabry Disease. J Genet Disor Genet Rep 5:4. doi: 10.4172/2327-5790.1000143. |
Abstract
Introduction: Enzyme replacement therapy (ERT) is the cornerstone of the treatment of Fabry disease (FD), with either agalsidase alfa or beta. Both preparations have been shown to be safe and effective in patients with FD, but there are very few data on the safety of ERT during pregnancy. Here we report a case of a 22-year-old woman with FD who received ERT with agalsidase alfa during the pregnancy.
Case report: The patient, a 22-year-old woman, was diagnosed with FD three years prior to pregnancy. Because of the presence of pain and proteinuria, she started treatment with agalsidase alfa (0.2 mg/kg every 2 weeks) with a substantial amelioration of the disease over time. When the patient informed us that she was pregnant, consensus was reached on continuation of ERT during pregnancy. The dose and frequency of intravenous ERT remained unchanged throughout pregnancy and agalsidase alfa infusions were well tolerated. At a gestational age of 39 weeks, the patient gave birth a healthy boy via a natural delivery.
Discussion: In our opinion, and supported by the findings of literature, pregnancy should not be a contraindication of ERT. ERT with agalsidase alfa during pregnancy seems to be well tolerated, without negative effects on the mother or child. Keywords Fabry disease; Enzyme replacement therapy; Agalsidase alfa; Pregnancy
